More News out on $ISOLF, it looks like they just closed another deal!
VANCOUVER, British Columbia, Dec. 08, 2017 (GLOBE NEWSWIRE) -- Isodiol International Inc. (CSE:ISOL) (OTC:ISOLF) (FSE:LB6A.F) (the “Company” or “Isodiol”), a global bioactive phytoceutical innovator specializing in the development of pharmaceutical and wellness products, announced today that it has entered into a definitive agreement with C3 Global Biosciences™ (C3GBS), a cause-driven organization committed to developing sustainable health solutions through the advancement of cannabis science.
This news is in connection with Isodiol’s previous announcement affirming that the Company had entered into a binding agreement with C3GBS. The official press release can be viewed here.
“At Isodiol, we believe that the ideation, creation, and evaluation of new ideas, is an interconnected process that drives innovation forward,” said Marcos Agramont, CEO of Isodiol. “C3GBS’s world-class team has a clear mission, focused strategy and healthy culture – all of which we expect will support the creation of value over the long term for Isodiol, our shareholders, and society.”
C3GBS’ strategy involves using science and technology-based innovation to deliver better patient outcomes in areas of healthcare with the utmost need. With C3GBS, Isodiol seeks to develop and advance proprietary, pharmaceutical-grade CBD Bioactive products that can produce positive real-world outcomes for patients and healthcare providers.
“C3GBS is an expert in conducting research, turning insights into tangible products, and incorporating those products into treatment programs, which are then evaluated with academic rigor,” said Agramont. “They are well-prepared for a world with both a growing and aging population that has evolving healthcare needs.”
